Forodesine in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma: An Evidence-Based Review

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s140756
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Correction To: Multicenter Phase 1/2 Study of Forodesine in Patients With Relapsed Peripheral T Cell Lymphoma

Annals of Hematology
MedicineHematology
2018English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PRELIMINARY RESULTS OF ASTX660, a NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-Cell LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chidamide in the Treatment of Peripheral T-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2017English

Recent Advances in the Treatment of Peripheral T‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2018English

Strategies for Relapsed Peripheral T-Cell Lymphoma: The Tail That Wags the Curve

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy